Palivizumab Injection

What This Palivizumab Shortage Record Means

The FDA Drug Shortages database lists this record for Palivizumab Injection (brand: SYNAGIS) from Swedish Orphan Biovitrum AB with a current status of To Be Discontinued. The affected dosage form is Injection, presented as Synagis, Injection, 50 mg/.5 mL (NDC 66658-230-01). Shortages are tracked at the manufacturer and presentation level — other manufacturers or formulations of the same generic may remain available, which is why pharmacists often can source a working substitute even when one record is flagged.

This shortage was first reported on Aug 13, 2025 and was last updated Aug 13, 2025. The FDA cites the following reason: Discontinuation of the manufacture of the drug. There is 1 other current record in this database covering the same generic, which gives a fuller picture of how disruption is playing out across manufacturers and dosage forms.

A shortage listing is a supply-side signal, not a patient-level instruction. Access can vary dramatically by pharmacy, region, hospital system, and insurance formulary — local pharmacists have real-time visibility that a national database cannot provide. Therapeutic substitutes often exist in the same class, but switching decisions belong with your prescriber, who weighs efficacy, dosing conversion, interaction profile, and personal history. This page summarizes public FDA data for educational reference only and is not medical advice. If your medication is affected, contact your pharmacist and prescriber to plan an appropriate response.